(MM) News - NBS

Diageo Terminates Heineken Partnership in South Africa

LONDON—Diageo PLC said it would terminate its partnership with Heineken NV in South Africa, as the world's largest spirits maker moves to...

Proxy Statement (definitive) (def 14a)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of theSecurities...

Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities...

Current Report Filing (8-k)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 8-K CURRENT REPORTPursuant to Section 13 or 15(d) of the...

NeoStem Announces Plans to Change Name to Caladrius Biosciences Reflecting Transformation Into Immunotherapy Company

NEW YORK, May 29, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a...

Current Report Filing (8-k)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 8-K CURRENT REPORTPursuant to Section 13 or 15(d) of the...

Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)

Filed Pursuant to Rule 424(b)(2)Registration No. 333-183543PROSPECTUS SUPPLEMENT (To the Prospectus dated October 3...

NeoStem Prices $25,000,000 Public Offering of Common Stock

NEW YORK, May 27, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), announced...

Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)

Issuer Free Writing ProspectusFiled Pursuant to Rule 433(f)Registration Statement No. 333-183543Neostem, Inc.Free Writing Prospectus Published or...

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Filed Pursuant to Rule 424(b)(5)Registration No. 333-183543The information in this preliminary prospectus supplement and the accompanying...

NeoStem Announces Proposed Public Offering of Common Stock

NEW YORK, May 27, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company...

NeoStem Announces Dr. Merrick Ross of MD Anderson Cancer Center as Lead Principal Investigator for Pivotal Phase 3 Trial for ...

NEW YORK, May 26, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

(MM) (NBS)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

NBS News

Diageo Terminates Heineken Partnership in South Africa

Proxy Statement (definitive) (def 14a)

Additional Proxy Soliciting Materials (definitive) (defa14a)

Current Report Filing (8-k)

NeoStem Announces Plans to Change Name to Caladrius Biosciences Reflecting Transformation Into Immunotherapy Company

Current Report Filing (8-k)

Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)

NeoStem Prices $25,000,000 Public Offering of Common Stock

Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

NeoStem Announces Proposed Public Offering of Common Stock

NeoStem Announces Dr. Merrick Ross of MD Anderson Cancer Center as Lead Principal Investigator for Pivotal Phase 3 Trial for ...

Turning Cancer Against Itself: Major Grant Advances Pioneering Melanoma Therapy at NeoStem

Quarterly Report (10-q)

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

NBS Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

(MM) (NBS) News

(MM) (NBS)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

NBS News

Diageo Terminates Heineken Partnership in South Africa

Proxy Statement (definitive) (def 14a)

Additional Proxy Soliciting Materials (definitive) (defa14a)

Current Report Filing (8-k)

NeoStem Announces Plans to Change Name to Caladrius Biosciences Reflecting Transformation Into Immunotherapy Company

Current Report Filing (8-k)

Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)

NeoStem Prices $25,000,000 Public Offering of Common Stock

Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

NeoStem Announces Proposed Public Offering of Common Stock

NeoStem Announces Dr. Merrick Ross of MD Anderson Cancer Center as Lead Principal Investigator for Pivotal Phase 3 Trial for ...

Turning Cancer Against Itself: Major Grant Advances Pioneering Melanoma Therapy at NeoStem

Quarterly Report (10-q)

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

NBS Discussion

Your Recent History